IP Library Granted Patent US 12,428,442
Granted Patent B2
US 12,428,442 · App. 18/316,932 · Granted Sep 30, 2025

Compounds, compositions and methods for synthesis

Inventors: David Charles Donnell Butler (Medford, MA); Christopher P. Hencken (Boston, MA); Naoki Iwamoto (Boston, MA); Pachamuthu Kandasamy (Lexington, MA); Alvaro Andres Lanao (Middlebury, CT); Genliang Lu (Winchester, MA); Mamoru Shimizu (Arlington, MA); Sethumadhavan Divakaramenon (Lexington, MA); Chandra Vargeese (Schwenksville, PA); Gopal Reddy Bommineni (Belmont, MA); Subramanian Marappan (Acton, MA)
Assignee: WAVE LIFE SCIENCES LTD.
C07H21/04C07C213/00C07C215/20C07C215/44C07D207/08C07D211/22C07F7/0812C07F7/083C07F9/6564C07H19/06C07C2601/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,428,442
App. No.
18/316,932
Granted
Sep 30, 2025
Kind
B2
Abstract

The present disclosure, among other things, provides technologies for synthesis, including reagents and methods for stereoselective synthesis. In some embodiments, the present disclosure provides compounds useful as chiral auxiliaries. In some embodiments, the present disclosure provides reagents and methods for oligonucleotide synthesis. In some embodiments, the present disclosure provides reagents and methods for chirally controlled preparation of oligonucleotides. In some embodiments, technologies of the present disclosure are particularly useful for constructing challenging internucleotidic linkages, providing high yields and stereoselectivity.

Claims (49)

1. A compound having the structure of formula V-b:

or a salt thereof, wherein:

P L is P;

is of such a structure that

is a compound of formula I-e or a salt thereof:

wherein:

-L 8 -H is the —OH shown in formula I-e;

t is 1;

Ring A is an optionally substituted 6-membered ring having 0-4 heteroatoms;

each of R 1 , R 3 , R 4 , and R 5 is independently —H, -L s -R, halogen, —CN, —NO 2 , -L s -Si(R) 3 , —OR, —SR, or —N(R) 2 ;

R 6 is —H;

—NHR 5 is —NR 5 R 6 shown in formula I-e;

each L s is independently a covalent bond, or a bivalent, optionally substituted, linear or branched group selected from a C 1-30 aliphatic group and a C 1-30 heteroaliphatic group having 1-10 heteroatoms, wherein one or more methylene units are optionally and independently replaced by an optionally substituted group selected from C 1-6 alkylene, C 1-6 alkenylene, —C≡C—, a bivalent C 1 -C 6 heteroaliphatic group having 1-5 heteroatoms, —C(R′) 2 —, -Cy-, —O—, —S—, —S—S—, —N(R′)—, —C(O)—, —C(S)—, —C(NR′)—, —C(O)N(R′)—, —N(R′)C(O)N(R′)—, —N(R′)C(O)O—, —S(O)—, —S(O) 2 —, —S(O) 2 N(R′)—, —C(O)S—, —C(O)O—, —P(O)(OR′)—, —P(O)(SR′)—, —P(O)(R′)—, —P(O)(NR′)—, —P(S)(OR′)—, —P(S)(SR′)—, —P(S)(R′)—, —P(S)(NR′)—, —P(R′)—, —P(OR′)—, —P(SR′)—, —P(NR′)—, —P(OR′)[B(R′) 3 ]—, —OP(O)(OR′)O—, —OP(O)(SR′)O—, —OP(O)(R′)O—, —OP(O)(NR′)O—, —OP(OR′)O—, —OP(SR′)O—, —OP(NR′)O—, —OP(R′)O—, and —OP(OR′)[B(R′) 3 ]O—, and one or more carbon atoms are optionally and independently replaced with Cy L ;

each -Cy- is independently an optionally substituted bivalent group selected from a C 3-20 cycloaliphatic ring, a C 6-20 aryl ring, a 5-20 membered heteroaryl ring having 1-10 heteroatoms, and a 3-20 membered heterocyclyl ring having 1-10 heteroatoms;

each Cy L is independently an optionally substituted tetravalent group selected from a C 3-20 cycloaliphatic ring, a C 6-20 aryl ring, a 5-20 membered heteroaryl ring having 1-10 heteroatoms, and a 3-20 membered heterocyclyl ring having 1-10 heteroatoms;

each R′ is independently —R, —C(O)R, —C(O)OR, or —S(O) 2 R;

BA is an optionally substituted group selected from a natural nucleobase moiety and a modified nucleobase moiety;

each R s is independently —H, halogen, —CN, —N 3 , —NO, —NO 2 , -L s -R′, -L s -Si(R) 3 , -L s -OR′, -L s -SR′, -L s -N(R′) 2 , —O-L s -R′, —O-L s -Si(R) 3 , —O-L s -OR′, —O-L s -SR′, or —O-L s -N(R′) 2 ;

Ring A s is

wherein each of R 2s and R 4s is independently R s ;

R 5s is R s ;

each R is independently —H, or an optionally substituted group selected from C 1-30 aliphatic, C 1-30 heteroaliphatic having 1-10 heteroatoms, C 6-30 aryl, C 6-30 arylaliphatic, C 6-30 arylheteroaliphatic having 1-10 heteroatoms, 5-30 membered heteroaryl having 1-10 heteroatoms, and 3-30 membered heterocyclyl having 1-10 heteroatoms, or

two R groups are optionally and independently taken together to form a covalent bond, or:

two or more R groups on the same atom are optionally and independently taken together with the atom to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the atom, 0-10 heteroatoms; or

two or more R groups on two or more atoms are optionally and independently taken together with their intervening atoms to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the intervening atoms, 0-10 heteroatoms.

2. The compound of claim 1 , wherein R 3 is —H.

3. The compound of claim 2 , wherein R 1 is optionally substituted C 1-6 aliphatic.

4. The compound of claim 3 , wherein R 1 is methyl.

5. The compound of claim 2 , wherein R 1 is optionally substituted phenyl.

6. The compound of claim 2 , wherein R 5 is optionally substituted C 1-6 aliphatic.

7. The compound of claim 3 , wherein R 5 is optionally substituted C 1-6 aliphatic.

8. The compound of claim 5 , wherein R 5 is optionally substituted C 1-6 aliphatic.

9. The compound of claim 6 , wherein R 5 is methyl.

10. The compound of claim 7 , wherein R 5 is methyl.

11. The compound of claim 8 , wherein R 5 is methyl.

12. The compound of claim 1 , wherein BA is an optionally substituted group which group is selected from

and tautomeric forms thereof.

13. The compound of claim 12 , wherein R 2s is —H.

14. The compound of claim 12 , wherein R 2s is —F.

15. The compound of claim 12 , wherein R 2s is —OR, wherein R is optionally substituted C 1-6 aliphatic.

16. The compound of claim 12 , wherein R 2s is —OMe.

17. The compound of claim 12 , wherein R 2s is —MOE.

18. The compound of claim 12 , wherein Ring A s is optionally substituted

19. The compound of claim 1 , wherein the compound of formula I-e

or a salt thereof.

20. The compound of claim 1 , wherein the compound of formula I-e

or a salt thereof.

21. The compound of claim 1 , wherein the compound of formula I-e

or a salt thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 18, 2023
From: BUTLER, DAVID CHARLES DONNELL; HENCKEN, CHRISTOPHER P.; IWAMOTO, NAOKI; KANDASAMY, PACHAMUTHU; LANAO, ALVARO ANDRES; LU, GENLIANG; SHIMIZU, MAMORU; DIVAKARAMENON, SETHUMADHAVAN; VARGEESE, CHANDRA; BOMMINENI, GOPAL REDDY; MARAPPAN, SUBRAMANIAN
To: WAVE LIFE SCIENCES LTD.
Reel/Frame 064640/0323 →
Continuity (4)
Continuation 16624896
Provisional Application 62560169 · Sep 18, 2017
Provisional Application 62523175 · Jun 21, 2017
Related Publication 20240174710A1 · May 30, 2024
References Cited (180)
US 5221736A · Coolidge et al. · 1993 [cited by applicant]
US 6384209B1 · Tang et al. · 2002 [cited by applicant]
US 8420821B2 · Matsuda et al. · 2013 [cited by applicant]
US 8470987B2 · Wada et al. · 2013 [cited by applicant]
US 8729036B2 · Zamore et al. · 2014 [cited by applicant]
US 8822671B2 · Shimizu et al. · 2014 [cited by applicant]
US 8859755B2 · Wada et al. · 2014 [cited by applicant]
US 9394333B2 · Wada et al. · 2016 [cited by applicant]
US 9476044B2 · Tuschl et al. · 2016 [cited by applicant]
US 9598458B2 · Shimizu et al. · 2017 [cited by applicant]
US 9605019B2 · Verdine et al. · 2017 [cited by applicant]
US 9617547B2 · Gemba · 2017 [cited by applicant]
US 9695211B2 · Wada et al. · 2017 [cited by applicant]
US 9744183B2 · Verdine et al. · 2017 [cited by applicant]
US 9982257B2 · Butler et al. · 2018 [cited by applicant]
US 10144933B2 · Gemba et al. · 2018 [cited by applicant]
US 10149905B2 · Gemba et al. · 2018 [cited by applicant]
US 10160969B2 · Meena et al. · 2018 [cited by applicant]
US 10167309B2 · Shimizu et al. · 2019 [cited by applicant]
US 10280192B2 · Verdine et al. · 2019 [cited by applicant]
US 10307434B2 · Verdine et al. · 2019 [cited by applicant]
US 10322173B2 · Gemba et al. · 2019 [cited by applicant]
US 10329318B2 · Wada et al. · 2019 [cited by applicant]
US 10428019B2 · Wada et al. · 2019 [cited by applicant]
US 10450568B2 · Butler et al. · 2019 [cited by applicant]
US 10479995B2 · Vargeese et al. · 2019 [cited by applicant]
US 10590413B2 · Butler et al. · 2020 [cited by applicant]
US 10696711B2 · Shimizu et al. · 2020 [cited by applicant]
US 10724035B2 · Vargeese et al. · 2020 [cited by applicant]
US 10815482B2 · Meena et al. · 2020 [cited by applicant]
US 11013757B2 · Zhang et al. · 2021 [cited by applicant]
US 11136346B2 · Shimizu et al. · 2021 [cited by applicant]
US 11596646B2 · Zhang et al. · 2023 [cited by applicant]
US 11597927B2 · Vargeese et al. · 2023 [cited by applicant]
US 11603532B2 · Vargeese et al. · 2023 [cited by applicant]
US 11634710B2 · Frank-Kamenetsky et al. · 2023 [cited by applicant]
US 11643657B2 · Butler et al. · 2023 [cited by applicant]
US 11718638B2 · Butler et al. · 2023 [cited by applicant]
US 11739325B2 · Vargeese et al. · 2023 [cited by applicant]
US 11873316B2 · Butler et al. · 2024 [cited by applicant]
US 20130345462A1 · Matsuda et al. · 2013 [cited by applicant]
US 20150211006A1 · Butler et al. · 2015 [cited by applicant]
US 20190127733A1 · Butler et al. · 2019 [cited by applicant]
US 20190249173A1 · Vargeese et al. · 2019 [cited by applicant]
US 20190264267A1 · Yang et al. · 2019 [cited by applicant]
US 20190375774A1 · Butler et al. · 2019 [cited by applicant]
US 20190390197A1 · Butler et al. · 2019 [cited by applicant]
US 20200080083A1 · Vargeese et al. · 2020 [cited by applicant]
US 20200362337A1 · Dodart et al. · 2020 [cited by applicant]
US 20210032620A1 · Vargeese et al. · 2021 [cited by applicant]
US 20210115444A1 · Meena et al. · 2021 [cited by applicant]
US 20210198305A1 · Vargeese et al. · 2021 [cited by applicant]
US 20210254062A1 · Zhang et al. · 2021 [cited by applicant]
US 20220098585A1 · Brown et al. · 2022 [cited by applicant]
US 20220127301A1 · Shimizu et al. · 2022 [cited by applicant]
US 20220145300A1 · Liu et al. · 2022 [cited by applicant]
US 20220162598A1 · Vargeese et al. · 2022 [cited by applicant]
US 20220401467A1 · Zhang et al. · 2022 [cited by applicant]
US 20230089442A1 · Kandasamy et al. · 2023 [cited by applicant]
US 20230136645A1 · Butler et al. · 2023 [cited by applicant]
US 20230145795A1 · Byrne et al. · 2023 [cited by applicant]
US 20230203087A1 · Kandasamy et al. · 2023 [cited by applicant]
US 20230220384A1 · Monian et al. · 2023 [cited by applicant]
US 20230295617A1 · Vargeese et al. · 2023 [cited by applicant]
US 20230295619A1 · Maguire et al. · 2023 [cited by applicant]
US 20230329201A1 · Yang et al. · 2023 [cited by applicant]
US 20230348524A1 · Bowman et al. · 2023 [cited by applicant]
US 20230392137A1 · Monian et al. · 2023 [cited by applicant]
US 20240026358A1 · Monian et al. · 2024 [cited by applicant]
US 20240109931A1 · Vargeese et al. · 2024 [cited by applicant]
US 20240117347A1 · Butler et al. · 2024 [cited by applicant]
US 20240132894A1 · Vargeese et al. · 2024 [cited by applicant]
US 20240150756A1 · Frank-Kamenetsky et al. · 2024 [cited by applicant]
US 20240175016A1 · Liu et al. · 2024 [cited by applicant]
US 20240175018A1 · Vargeese et al. · 2024 [cited by applicant]
US 20240229026A1 · Butler et al. · 2024 [cited by applicant]
CN 101437801A · 2009 [cited by applicant]
CN 102596204A · 2012 [cited by applicant]
CN 104661664A · 2015 [cited by applicant]
CN 104684893A · 2015 [cited by applicant]
JP 62289589A · 1987 [cited by applicant]
JP 2003238586A · 2003 [cited by applicant]
JP 2015528002A · 2015 [cited by applicant]
WO WO9419363A1 · 1994 [cited by applicant]
WO WO2004007718A2 · 2004 [cited by applicant]
WO WO2005014609A2 · 2005 [cited by applicant]
WO WO2005023828A1 · 2005 [cited by applicant]
WO WO2005028494A1 · 2005 [cited by applicant]
WO WO2005070859A1 · 2005 [cited by applicant]
WO WO2005085272A1 · 2005 [cited by applicant]
WO WO2005092909A1 · 2005 [cited by applicant]
WO WO2010064146A2 · 2010 [cited by applicant]
WO WO2011005761A1 · 2011 [cited by applicant]
WO WO2011034072A1 · 2011 [cited by applicant]
WO WO2011108682A1 · 2011 [cited by applicant]
WO WO2012039448A1 · 2012 [cited by applicant]
WO WO2012073857A1 · 2012 [cited by applicant]
WO WO2013012758A1 · 2013 [cited by applicant]
WO WO2014010250A1 · 2014 [cited by applicant]
WO WO2014010718A1 · 2014 [cited by applicant]
WO WO2014012081A2 · 2014 [cited by applicant]
WO WO2015107425A2 · 2015 [cited by applicant]
WO WO2015108046A1 · 2015 [cited by applicant]
WO WO2015108047A1 · 2015 [cited by applicant]
WO WO2015108048A1 · 2015 [cited by applicant]
WO WO2017015555A1 · 2017 [cited by applicant]
WO WO2017015575A1 · 2017 [cited by applicant]
WO WO2017062862A2 · 2017 [cited by applicant]
WO WO2017160741A1 · 2017 [cited by applicant]
WO WO2017192664A1 · 2017 [cited by applicant]
WO WO2017192679A1 · 2017 [cited by applicant]
WO WO2017210647A1 · 2017 [cited by applicant]
WO WO2018022473A1 · 2018 [cited by applicant]
WO WO2018067973A1 · 2018 [cited by applicant]
WO WO2018098264A1 · 2018 [cited by applicant]
WO WO2018223056A1 · 2018 [cited by applicant]
WO WO2018223073A1 · 2018 [cited by applicant]
WO WO2018223081A1 · 2018 [cited by applicant]
WO WO2018237194A1 · 2018 [cited by applicant]
WO WO2019002237A1 · 2019 [cited by applicant]
WO WO2019032607A1 · 2019 [cited by applicant]
WO WO2019032612A1 · 2019 [cited by applicant]
WO WO2019055951A1 · 2019 [cited by applicant]
WO WO2019075357A1 · 2019 [cited by applicant]
WO WO2019200185A1 · 2019 [cited by applicant]
WO WO2019217784A1 · 2019 [cited by applicant]
WO WO2020118246A1 · 2020 [cited by applicant]
WO WO2020160336A1 · 2020 [cited by applicant]
WO WO2020191252A1 · 2020 [cited by applicant]
WO WO2020196662A1 · 2020 [cited by applicant]
WO WO2020219981A2 · 2020 [cited by applicant]
WO WO2020219983A2 · 2020 [cited by applicant]
WO WO2020227691A2 · 2020 [cited by applicant]
WO WO2021071788A2 · 2021 [cited by applicant]
WO WO2021071858A1 · 2021 [cited by applicant]
WO WO2021178237A2 · 2021 [cited by applicant]
WO WO2021234459A2 · 2021 [cited by applicant]
WO WO2021237223A1 · 2021 [cited by applicant]
WO WO2022046667A1 · 2022 [cited by applicant]
WO WO2022046723A1 · 2022 [cited by applicant]
WO WO2022099159A1 · 2022 [cited by applicant]
WO WO2023049475A1 · 2023 [cited by applicant]
WO WO2023049477A2 · 2023 [cited by applicant]
WO WO2023075766A1 · 2023 [cited by applicant]
WO WO2023076352A2 · 2023 [cited by applicant]
WO WO2023154528A1 · 2023 [cited by applicant]
WO WO2023168014A2 · 2023 [cited by applicant]
WO WO2023201095A2 · 2023 [cited by applicant]
WO WO2023220440A1 · 2023 [cited by applicant]
WO WO2024035946A1 · 2024 [cited by applicant]
U.S. Appl. No. 17/605,998, filed Oct. 22, 2021, Byrne et al. [cited by applicant]
U.S. Appl. No. 17/766,680, filed Apr. 5, 2022, Liu et al. [cited by applicant]
U.S. Appl. No. 18/062,422, filed Dec. 6, 2022, Butler et al. [cited by applicant]
U.S. Appl. No. 18/178,470, filed Mar. 3, 2023, Vargeese et al. [cited by applicant]
U.S. Appl. No. 18/204,895, filed Jun. 1, 2023, Vargeese et al. [cited by applicant]
U.S. Appl. No. 18/252,029, filed May 5, 2023, Monian et al. [cited by applicant]
U.S. Appl. No. 18/305,195, filed Apr. 21, 2023, Frank-Kamenetsky et al. [cited by applicant]
U.S. Appl. No. 18/522,146, filed Nov. 28, 2023, Butler et al. [cited by applicant]
Ami, E. and Ohrui, H., Lipase-catalyzed Kinetic Resolution of (+)-trans- and cis-2-Azidocycloalkanols, Biosci. Biotechnol. Biochem., 63(12):2150-2156 (1999). [cited by applicant]
Bench, B. J. et al., Proline Promoted Synthesis of Ring-Fused Homodimers: Self-Condensation of α,β-Unsaturated Aldehydes±, J. Org. Chem., 71(25):9458-9463 (2006). [cited by applicant]
Cui, H. et al., Direct aldol condensation reaction of ethyl diazoacetate with trfluoromethyl ketones, Tetra., 67(44):8470-8476 (2011). [cited by applicant]
Demir, A. S. et al., Novel Enantioselective Synthesis of Both Enantiomers of Furan-2-yl Amines and Amino Acids, Helvet. Chim. Acta, 86(1):91-105 (2003). [cited by applicant]
Gil-Av, E., Condensation Products of the Epimeric 2-Aminocyclohexanols with Carbonyl Compounds, J. Am. Chem. Soc., 81(7):1602-1606 (1959). [cited by applicant]
International Search Report for PCT/US2018/038835, 4 pages (mailed Oct. 29, 2018). [cited by applicant]
International Search Report for PCT/US2018/051398, 4 pages (mailed Feb. 1, 2019). [cited by applicant]
Koch, T., LNA Therapeutics—update, Navigate the phosphorothioate diastereoisomer space, Roche pRED RNA Therapeutics Research, EuroTIDES, PostillionConventionCenter, Amsterdam, Netherlands (Nov. 6-9, 2018). [cited by applicant]
Lysenko, I. L. and Kulinkovich, O. G., Stereoselective Synthesis of (7aS)-1-Methylenehexahyrdro-1H-pyrrolizine and (-)-Heliotridane from N-Diphenylmethyl-(S)-proline Ethyl Ester, Russ. Jrnl. Org. Chem., 41:70-74 (2005). [cited by applicant]
Masui, M. and Takayuki, S., A practical method for preparation of optically pure oxazaborolidines from α-Pinene, Tetra., 51(30):8363-8370 (1995). [cited by applicant]
Pubchem, Compound Summary for CID 522583, Create Date: Mar. 27, 2005, 16 pages (Retrieved Aug. 23, 2018). Retrieved from the Internet: <URL: https://pubchem.ncbi.nlm.nih.gov/compound/522583>. [cited by applicant]
Written Opinion for PCT/US2018/038835, 6 pages (mailed Oct. 29, 2018). [cited by applicant]
Written Opinion for PCT/US2018/051398, 16 pages (mailed Feb. 1, 2019). [cited by applicant]
Xie, J. et al., Organocatalytic and direct asymmetric vinylogous Michael addition of α,α-dicyanoolefins to α,β-unsaturated aldehydes, Chem. Commun., 14:1563-1565 (2006). [cited by applicant]
U.S. Appl. No. 18/613,034, filed Mar. 21, 2024, Vargeese et al. [cited by applicant]
U.S. Appl. No. 18/695,346, filed Mar. 25, 2024, Monian et al. [cited by applicant]
U.S. Appl. No. 18/695,348, filed Mar. 25, 2024, Acker et al. [cited by applicant]
U.S. Appl. No. 18/704,629, filed Apr. 25, 2024, Byrne et al. [cited by applicant]
U.S. Appl. No. 18/836,993, filed Aug. 8, 2024, Kandasamy et al. [cited by applicant]
U.S. Appl. No. 18/843,171, filed Aug. 30, 2024, Hu et al. [cited by applicant]
U.S. Appl. No. 18/856,553, filed Oct. 11, 2024, Lu et al. [cited by applicant]
Zon, G., Oligonucleoside Phosphorothioates, Methods in Mole. Biol., 20:165-189 (1993). [cited by applicant]
Cited By (2)
US 12,590,115 US 12,674,168